- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03825861
Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer (FOLFIRINOX)
Phase II single-arm study designed to evaluate the efficacy and safety of preoperative chemotherapy with FOLFIRINOX regimen. The investigators will include 27 patients with resectable locally advanced gastric cancer. They will receive preoperative chemotherapy with FOLFIRINOX regimen by long-term catheter every 14 days for 8 cycles accounting for a total of 4 months of systemic treatment. In the period between 4 and 8 weeks of the last cycle, restaging tests will be performed and if there is no metastatic progression of disease, the patient will undergo surgical treatment with curative intention. The objective is to evaluate whether preoperative treatment with FOLFIRINOX regimen involving continuous infusion and bolus infusion of 5-fluoruracil, irinotecan bolus and oxaliplatin bolus is effective and safe in the neoadjuvant treatment of locally advanced gastric cancer.
The planned recruitment period is 48 months (4 years). There will be a total of 4 months of preoperative chemotherapy. In case of limiting toxicity or disease progression, chemotherapy will be suspended and patients may undergo resection of the primary neoplasia at the discretion of the surgical team of the institution. Patients will be followed for 5 years after entry of the last participant in the protocol for OS and PFS evaluation. The end of the study will occur when the last participant completes their last follow-up visit, which should occur no later than 60 months after enrollment in the study.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tiago B. Castria, MD PhD
- Phone Number: +551138934531
- Email: tiagobiachi@yahoo.com.br
Study Locations
-
-
-
São Paulo, Brazil, 01246-000
- Recruiting
- Instituto do Cancer do Estado de Sao Paulo
-
Contact:
- Tiago Castria, MD PhD
- Phone Number: +5511 3893-2000
- Email: tiagobiachi@yahoo.com.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological diagnosis of gastric adenocarcinoma that is amenable to surgical resection at diagnosis, with locally advanced disease criteria for clinical evaluation (T3 tumors, T4 tumors and / or regional lymph node involvement).
- Absence of metastatic disease at a distance (computerized tomography, diagnostic laparoscopy and peritoneal lavage).
- Age 18-75 years.
- Clinical functionality by the ECOG scale between 0 and 1.
- Preserved renal function (creatinine clearance greater than 50 mL / min).
- Signature of Informed Consent Form
Exclusion Criteria:
- Active neoplasm of another primary site other than non-melanoma skin carcinoma.
- Lesions of the esophagogastric transition
- Unresectable lesions by computed tomography and / or diagnostic laparoscopy.
- Obstructive tumors (acute intestinal occlusion or subocclusion).
- Tumors with signs of significant or persistent bleeding.
- Carcinoma in situ.
- Different histological type of adenocarcinoma.
- Gastric stump tumors.
- Previous chemotherapeutic or radiotherapy treatment.
- Current pregnancy or breastfeeding.
- Total bilirubin above 1.5mg / dL.
- Hepatic transaminases greater than 1.5 times the upper limit of normality.
- Decompensated and / or symptomatic cardiomyopathy: congestive heart failure with functional class greater than 2 by the New York Heart Association; active coronary disease; uncontrolled cardiac arrhythmia; history of acute myocardial infarction in the last 6 months.
- Psychological, familial, social or even geographical condition that potentially hinders adherence to the study protocol and the pre-established follow-up.
- Current or previous psychiatric or neurological diagnosis that is decompensated, compromises the cognition, functionality or adherence to the proposed treatment.
- Other comorbidities that are decompensated at the time of treatment.
- Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFIRINOX
Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
|
Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Complete Response (pCR)
Time Frame: 4-8 weeks after neoadjuvant chemotherapy complete
|
To evaluate the Pathologic Complete Response (pCR).
|
4-8 weeks after neoadjuvant chemotherapy complete
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival (DFS)
Time Frame: At 2, 3 and 5 years after preoperative treatment with FOLFIRINOX regimen.
|
Evaluate Disease-free survival (DFS).
|
At 2, 3 and 5 years after preoperative treatment with FOLFIRINOX regimen.
|
Overall survival (OS)
Time Frame: At 2, 3 and 5 years after preoperative treatment with FOLFIRINOX regimen.
|
Evaluate Overall survival (OS).
|
At 2, 3 and 5 years after preoperative treatment with FOLFIRINOX regimen.
|
R0-resection rate
Time Frame: 4-8 weeks after neoadjuvant chemotherapy complete
|
Evaluate the R0 resection rate (absence of microscopic residual disease).
|
4-8 weeks after neoadjuvant chemotherapy complete
|
Rate of Treatment Completion
Time Frame: 4-8 weeks after neoadjuvant chemotherapy complete
|
Evaluate the rate of completion of treatment (chemotherapy and surgical approach).
|
4-8 weeks after neoadjuvant chemotherapy complete
|
Rate of adverse events
Time Frame: Through neoadjuvant chemotherapy (4 months)
|
Rate and description of adverse events
|
Through neoadjuvant chemotherapy (4 months)
|
Rate of Disease Progression
Time Frame: Through neoadjuvant chemotherapy (4 months)
|
Evaluate the rate of disease progression.
|
Through neoadjuvant chemotherapy (4 months)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 933/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on FOLFIRINOX
-
Fox Chase Cancer CenterRecruitingMetastatic Pancreatic CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCholangiocarcinomaNetherlands
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingMetastatic Pancreatic CancerFrance
-
Asan Medical CenterGreen Cross Corporation; Boryung Pharmaceutical Co., LtdRecruitingUrachal CancerKorea, Republic of
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingMetastatic Colorectal CancerFrance
-
King Faisal Specialist Hospital & Research CenterTerminatedBiliary Tract CancerSaudi Arabia
-
Cantargia ABCompletedMetastatic Pancreatic Ductal AdenocarcinomaSpain, France
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Cancer Non-resectableItaly
-
The University of Texas Health Science Center,...WithdrawnPancreatic Adenocarcinoma
-
Assiut UniversityUnknown